You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Vatalanib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Vatalanib?

Vatalanib is an investigational drug.

There have been 24 clinical trials for Vatalanib. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2003.

The most common disease conditions in clinical trials are Carcinoid Tumor, Neoplasms, and Neuroendocrine Tumors. The leading clinical trial sponsors are Novartis, National Cancer Institute (NCI), and Novartis Pharmaceuticals.

Recent Clinical Trials for Vatalanib
TitleSponsorPhase
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric CancerThe Affiliated Hospital of the Chinese Academy of Military Medical SciencesPhase 1/Phase 2
Apatinib for Metastatic Esophageal Cancer.Hangzhou Cancer HospitalPhase 2
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid TumorsNational Cancer Institute (NCI)Phase 1

See all Vatalanib clinical trials

Clinical Trial Summary for Vatalanib

Top disease conditions for Vatalanib
trials011223344Carcinoid TumorNeoplasmsNeuroendocrine TumorsNervous System Neoplasms[disabled in preview]
Top clinical trial sponsors for Vatalanib
trials01234567891011NovartisNational Cancer Institute (NCI)Novartis Pharmaceuticals[disabled in preview]

See all Vatalanib clinical trials

Vatalanib: A Promising VEGF Receptor Tyrosine Kinase Inhibitor

Introduction

Vatalanib, also known as PTK787, is a potent vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that has been under intense scrutiny for its potential in treating various types of cancer. Here, we delve into the development updates and market projections for this promising drug candidate.

Mechanism of Action

Vatalanib works by inhibiting the VEGF receptors, which are crucial for angiogenesis – the process of forming new blood vessels. In cancer, this process is often exploited by tumor cells to secure a blood supply necessary for their growth and metastasis. By blocking VEGF receptors, vatalanib disrupts the tumor's ability to form new blood vessels, thereby starving the tumor of the nutrients and oxygen it needs to grow[3][4].

Clinical Trials and Efficacy

Vatalanib has undergone extensive clinical trials, particularly in the treatment of metastatic colorectal cancer. Phase III trials have involved over 1,900 patients, with one trial evaluating patients with previously untreated colorectal cancer and another evaluating those with previously irinotecan-treated colorectal cancer that has progressed. These trials have shown promising results, including a significant reduction in tumor blood supply and tumor vascular response within 36 hours of treatment. The drug has demonstrated linear kinetics and good tolerability, with Joerg Reinhardt, PhD, noting that vatalanib provides a higher level of specificity to cancer cells with less toxicity[3].

Safety and Tolerability

Early clinical trials have indicated that vatalanib is well-tolerated. The drug has shown good safety profiles, with minimal adverse effects compared to other cancer therapies. This is a significant advantage, as it allows for the drug to be used in combination with other chemotherapy regimens without exacerbating side effects[3].

Market Projections

Approval Likelihood

Vatalanib has a moderate likelihood of approval, estimated at around 25%. This is based on its performance in clinical trials and the specific mechanisms it targets, which are critical in cancer therapy[3].

Projected Sales

The projected annual peak sales for vatalanib are substantial, estimated at $1.3 billion. This figure reflects the drug's potential impact on the market, particularly in the treatment of metastatic colorectal cancer and other cancers where VEGF inhibition is beneficial[3].

Competitive Landscape

Vatalanib operates in a competitive landscape where other VEGF inhibitors, such as bevacizumab, are already established. However, vatalanib's specificity and lower toxicity profile position it as a promising alternative. Additionally, its potential use in combination therapies could further enhance its market position[4].

Future Directions

Combination Therapies

One of the key future directions for vatalanib is its use in combination with other chemotherapy agents. Studies have shown that combining vatalanib with standard chemotherapy regimens can enhance treatment outcomes. This approach is being explored in various clinical trials to maximize the drug's efficacy[3].

Expanding Indications

Beyond metastatic colorectal cancer, vatalanib is being investigated for its potential in treating other types of cancer. Its mechanism of action makes it a candidate for treating tumors that are highly dependent on angiogenesis, such as certain types of sarcomas and breast cancers[4].

Regulatory Environment

The regulatory environment for vatalanib is favorable, with ongoing Phase III trials and a clear path towards potential FDA approval. The drug's performance in clinical trials and its safety profile have been positive, which bodes well for its regulatory prospects[3].

Conclusion

Vatalanib is a significant player in the field of cancer therapeutics, particularly in the inhibition of VEGF receptors. Its development has shown promising results, and market projections indicate a strong potential for this drug candidate.

Key Takeaways

  • Mechanism of Action: Vatalanib inhibits VEGF receptors, disrupting tumor angiogenesis.
  • Clinical Trials: Phase III trials have shown significant reductions in tumor blood supply and good tolerability.
  • Market Projections: Estimated annual peak sales of $1.3 billion with a 25% likelihood of approval.
  • Future Directions: Potential use in combination therapies and expanding indications to other cancer types.
  • Regulatory Environment: Favorable regulatory prospects with ongoing Phase III trials.

FAQs

What is the primary mechanism of action of vatalanib?

Vatalanib works by inhibiting the VEGF receptors, which are crucial for the formation of new blood vessels that tumors need to grow.

What types of cancer is vatalanib being tested for?

Vatalanib is primarily being tested for metastatic colorectal cancer but is also being investigated for its potential in treating other types of cancer, such as certain sarcomas and breast cancers.

What are the projected annual peak sales for vatalanib?

The projected annual peak sales for vatalanib are estimated at $1.3 billion.

How does vatalanib compare to other VEGF inhibitors?

Vatalanib has a higher level of specificity to cancer cells and lower toxicity compared to other VEGF inhibitors, making it a promising alternative.

What is the current status of vatalanib in clinical trials?

Vatalanib is currently in Phase III clinical trials, with ongoing evaluations in patients with previously untreated and previously treated metastatic colorectal cancer.

Sources

  1. Pharmaceutical Executive: Predicting Success: A Pipeline Report[3].
  2. Onclive: Novel Molecular Targets for Drug Development in Non-GIST Sarcomas[4].
  3. PubMed: Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1[1].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.